Zhejiang CONBA Pharmaceutical Co.,Ltd.

600572

CNE000001H86

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
4.92 ^CNY	+0.20%		+0.41%	-2.57%

Apr. 19	Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 01	Tranche Update on Zhejiang CONBA Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 23, 2024.	CI

Tranche Update on Zhejiang CONBA Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 23, 2024.

April 31, 2024 at 10:05 pm EDT

From January 22, 2024 to March 31, 2024, the company has repurchased 25,705,695 shares, representing 1% for CNY 119.53 million. With this, the company has completed the repurchase of 25,705,695 shares, representing 1% for CNY 119.53 million under the buyback announced on January 23, 2024.

Latest news about Zhejiang CONBA Pharmaceutical Co.,Ltd.

Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 19	CI
Tranche Update on Zhejiang CONBA Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 23, 2024.	Mar. 31	CI
Shanghai-Listed Firms Actively Repurchase Shares as Regulators Focus on Market Value	Feb. 01	MT
Shanghai Dingjia Trading Co., Ltd. agreed to acquire 20% stake in Shanghai Kede Network Technology Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd. for CNY 26 million.	Jan. 31	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 400 million worth of its shares.	Jan. 22	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	Jan. 21	CI
CONBA Pharma Gets Nod to Trial Cough Medicine	Nov. 28	MT
CONBA Pharma Unit's Acetyl Cysteine Granules Chosen for China's Centralized Drug Procurement	Nov. 08	MT
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) added to S&P Global BMI Index	23-09-18	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) added to FTSE All-World Index	23-09-18	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-04	CI
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) completed the acquisition of 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd.	23-07-06	CI
CONBA Pharma Gets Drug Registration for Risperidone Oral Solution	23-05-25	MT
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) intends to acquire 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd for CNY 290 million.	23-04-28	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-18	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Zhejiang CONBA Pharmaceutical to Sell 7.8% Stake in Pharma Firm	23-03-20	CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. acquired remaining 7.6665% stake in Zhejiang CONBA Health Technology Co., Ltd from Gao Jing and Hu Xiaodan for CNY 21.9 million.	23-03-16	CI
Zhejiang Int'l Group Co.,Ltd. announced that it has received CNY 399.999996 million in funding from Zhejiang CONBA Pharmaceutical Co.,Ltd.	23-03-15	CI
CONBA Pharma's Azithromycin for Injection Passes Drug Regulator's Evaluation	23-02-24	MT
Zhejiang CONBA Pharmaceutical Co.,Ltd. agreed to acquire additional 12.3335% minority stake in Zhejiang CONBA Health Technology Co., Ltd from Hu Bei for CNY 35.3 million.	23-02-17	CI
CONBA Pharmaceutical Unit Sells Land For $17 Million	22-11-23	MT
CONBA Pharmaceutical Unit Gets Regulator's Nod For Acetylcysteine Granules.	22-11-23	MT

Chart Zhejiang CONBA Pharmaceutical Co.,Ltd.

Duration

Period

Chart Zhejiang CONBA Pharmaceutical Co.,Ltd.

More charts

Company Profile

Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.

Sector

Pharmaceuticals

Calendar

2024-05-10 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang CONBA Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.92

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD.	-2.57%	1.74B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.81%	43.34B
OTSUKA HOLDINGS CO., LTD.	+21.40%	21.96B
SANDOZ GROUP AG	+13.30%	14.09B
CIPLA LIMITED	+12.97%	13.64B
ZYDUS LIFESCIENCES LIMITED	+39.74%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-10.85%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+9.64%	5.22B

Generic Pharmaceuticals

Zhejiang CONBA Pharmaceutical Co.,Ltd.

Equities

600572

CNE000001H86

Pharmaceuticals

Tranche Update on Zhejiang CONBA Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 23, 2024.

EPS Revisions